Nanotechnology Now - Press Release: Nanostart subsidiary MagForce receives renowned business award

Home > Press > Nanostart subsidiary MagForce receives renowned business award

Abstract:
* STEP award 2010 winner in the category product/technology
* Prize awarded in recognition of company's innovation and growth potential
* "New therapy option for patients diagnosed with brain tumors"

Nanostart subsidiary MagForce receives renowned business award

Frankfurt / Berlin | Posted on November 17th, 2010

Nanostart subsidiary MagForce Nanotechnologies AG (FSE:MF6), a leader in the area of nanotechnology-based cancer treatment, has been selected as the 2010 recipient of the STEP award in the category "product/technology". "We are honored to receive the prestigious STEP award in recognition of MagForce's novel therapy for the treatment of brain tumors. Our innovative therapeutic approach uses nanoparticles, which are activated through the application of a magnetic field to produce heat within the tumor," said Dr. Peter Heinrich, CEO of MagForce. "Following our recent EU approval, we are focusing on building the commercial structures needed to launch our Nano-Cancer-therapy at leading German cancer centers in early 2011. Our transformation from a research and development company to a commercial business also signifies a new therapy option for patients diagnosed with brain tumors."

"We congratulate our majority-owned portfolio company MagForce Nanotechnologies on its achievement, particularly against such a field of outstanding nominees," commented Marco Beckmann, CEO of Nanostart AG. "This vote of confidence by the selection committee, comprised of experts from both science and industry, underscores the promising outlook for Nano-Cancer® therapy in the oncology market."

The STEP award, initiated by Infraserv Höchst and F.A.Z. Institute along with leading industry sponsors, was awarded for the fifth time this year. More than 100 companies competed in this year's STEP award. Small and mid-sized growth companies in innovative fields ranging from pharmaceuticals, chemicals, life science, biotechnology, and nanotechnology to medical and green technology are eligible to take part in the annual competition.

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.

####

About Nanostart
Nanostart AG (OTCQX: NASRY), headquartered in the German financial capital of Frankfurt, is the world’s leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary and venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. For further information, please visit www.nanostart.de.

About MagForce
MagForce Nanotechnologies AG is a leader in the area of nanotechnology-based cancer treatment and the first company worldwide to receive European approval for a medical product using nanoparticles. Its proprietary procedure, Nano-Cancer® therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. The company’s products, Nanotherm® and NanoActivator™, which are the components of the therapy, received EU-wide regulatory approval as medical devices for the treatment of brain tumors. For further information, please visit www.magforce.com.

For more information, please click here

Contacts:
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: